Table 5 Analysis of the relationship between CINV control and maintenance of usual daily food intake in the overall phase (day 1 to 5).

From: Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)

Variables

Subgroup

No. of patients

NEPA + DEX1 (n = 76)

No. of patients

NEPA + DEX4 (n = 76)

OR (95% CI)

p-value*

Usual daily food intake

Usual daily food intake

N

%

N

%

CR (overall phase)

Yes

58

45

77.6

57

45

78.9

3.82

0.001

No

18

8

44.4

19

10

52.6

(1.74; 8.35)

NSN (overall phase)

Yes

59

46

77.9

58

46

79.3

4.39

0.0004

No

17

7

41.2

18

9

50

(1.97; 9.77)

  1. NEPA fixed combination of netupitant and palonosetron, DEX1 dexamethasone day 1, DEX4 dexamethasone day 1 to 4, OR odds ratio, CI confidence interval, CR complete response (no vomiting and no rescue medication), NSN no significant nausea (none or mild nausea).
  2. *p-value was calculated using the Mantel–Haenszel chi-square test (two-tailed) stratified by treatment group.
Back to article page